LABORATORY THREE


BUSINESS PLAN


HEALTH PRODUCTS in CANADA
The words 'medicine' and 'health' have been used interchangeably - deliberately - by the pharmaceutical industry and the medical profession, for their mutual benefit, although the meanings are quite different. We expect this to be clarified post-NESARA: medical doctors will have to become truly 'doctors of health' rather than of medicine alone, and the health-care industry will be expanded officially to include all professionals in the field of health.

The use of the word 'drug' is also expected to change and prescriptions will be for health products or, in fewer cases, for actual drugs. There will be no place for a 'Food and Drug' administration as the two product fields are quite different, and it was established for the sole benefit of the pharmaceutical industry. New organizations will look after the safety of products used until the producers become self-controlling, and negative influences have been removed from their ranks.

As medical reports show that less than 30% of medical drugs passed for marketing undergo any significant testing, side-effects are naturally a recognized problem, and many are even life-threatening (as shown by the recent use of such 'approved' drugs as Vioxx and Celebrex). Research and development will be carried out to replace such products with safe alternatives. Dangers to health in the 21st Century are well-outlined on the website http://geocities.com/missionstmichael/. However, even more revealing is the report on planned world depopulation on the website http://geocities.com/newageinternational/DepopulationIntro.html.

This will give a tremendous boost both to the current and new manufacturers of natural health products and will result in a healthier, more productive population, who will spend less time in hospitals and clinics and be more able to enjoy life to its fullest.

IDENTIFYING THE RISKS
As the operation will not commence until adequate startup funding is provided, and there is no equivalent alternative supplier for the initial products, there is little risk that this service will not be highly regarded and sought after, and demand is expected to exceed supply before long.

PROFITABILITY
The production of effective, but not otherwise generally available, products; the low turnover of staff, through generous pay and benefit packages; and the high quality of personnel chosen, will contribute greatly to the viability of the operation, which will be enhanced by post-NESARA conditions for businesses in general (such as the removal of so-called 'income taxes'). However, profitability is not the primary aim except in that it provides additional funding for expansion of services or reduction of product cost.

COMPETITIVE ANALYSIS
There is no effective competition. Without the unconscionable profit-taking of the pharmaceutical industry as a whole, prices will be only a fraction of current medical drugs.

The market will be so great after the NESARA announcement and implementation of its benefits, that there will be room for all to participate in providing the needs of the general public in the field of health products. The byword of the Golden Age (21st Century) will be co-operation rather than competition, so efficiency, creativity and filling a need will play a major role in obtaining and maintaining adequate market share.

FINANCE
Projections are based upon startup costs being provided by philanthropic sources and the laboratory being operated by a federally incorporated non-profit corporation, i.e., on a non-profit basis, the benefactors being the general public (low-cost products); the staff (generous compensation); under-developed countries (free products or local employment opportunities through local facilities) and the originators (satisfaction in providing such facilities and such unique products).

Productivity is likely to be speeded up by the purchase of an existing facility. Only outright purchase will be considered, although the existing owners may be retained for consultancy on overall operations. Existing staff will be retained wherever possible.

No allowance has been made for excess income over expenditure, although this is likely by the second year of operation, as the facility is not profit-oriented but exists to provide a service to mankind.

COST OVERVIEW

Start-up Capital costs (estimated): ....................$103,018,050
Estimated annual operating costs: ........................ $6,058,433

CONSTRUCTION
It is not anticipated that construction will be undertaken as a number of existing laboratories will probably be discontinued in the post-NESARA era, as the use of pharmaceutical products drops drastically, and they will most likely be available for purchase. Some reconstruction may however be required for an existing facility.

COMPARISON WITH OTHER FACILITIES
Most laboratory facilities today manufacture pharmaceutical products. With the increasing public release of information on how little research goes into these products, and their dangerous side-effects, these laboratories and other manufacturing plants will be at a disadvantage compared to those producing natural products. Some have called themselves manufacturers of nutraceuticals, as a compromise, but this word too will likely fall out of use.

As safe products will be a major concern, the medical journal reports of inadequacies in this respect will spur the public - and hopefully also health institutions also - to turn to natural products without dangerous side-effects, rather than use what have been called 'pharmaceutical drugs' - at a ridiculously high cost. This should also prove a major attraction to health insurance firms as they find that their prescription costs will be drastically cut.

© Dr Milson Macleod 2004

Return to LABORATORY THREE INDEX Page
or go on to ......PRODUCTS Page

Your use of this site is subject to
Terms and Conditions of Use
See also our
Privacy Policy